Positive outcomes of first children treated with remestemcel-l for multisystem inflammatory syndrome (mis-c) and heart failure post-covid-19 published in pediatrics

New york, feb. 17, 2021 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that pediatrics (journal of the american academy of pediatrics) has published a paper on the first two children treated with mesoblast's mesenchymal stromal cell (msc) product candidate remestemcel-l for life-threatening multisystem inflammatory syndrome (mis-c) associated with covid-19.
MESO Ratings Summary
MESO Quant Ranking